ClinicalTrials.gg
CompletedNCT06052566Updated Oct 22, 2025Results posted

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

A Phase 1 interventional study of Efinopegdutide in Non-alcoholic Steatohepatitis and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
10th of 10
22 · median 113
Started
2023
with 1 other
Phase 1
3 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 9th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.

03

Conditions studied

  • Non-alcoholic Steatohepatitis
  • Hepatic Impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • A participant assigned female at birth is eligible to participate if not pregnant or breastfeeding, is not a participant of (POCBP), or is a POCBP and agrees to follow guidance during the study intervention period and for at least 35 days after the last dose of study intervention.
  • For participants with moderate or severe hepatic impairment: Have a diagnosis of chronic (>6 months), stable, hepatic impairment with features of cirrhosis due to any etiology (stability of hepatic disease should correspond to no acute episodes of illness within the previous 2 months due to deterioration in hepatic function).

Exclusion criteria

Exclusion Criteria:

  • History of cancer ().
  • Had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Participants with moderate or severe hepatic impairment who are positive for (HIV)-1 or HIV-2 at the prestudy (screening) visit.
  • Participants with moderate or severe hepatic impairment who received antiviral and/or immune modulating therapy for virus (HBV) or virus (HCV) within 90 days prior to study start.
  • Healthy participants who are unable to refrain from or anticipate the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study (including washout intervals between treatment periods), until the poststudy visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Efinopegdutide in Participants with Moderate Hepatic Impairment

    Participants with moderate hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection.

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide in Participants with Severe Hepatic Impairment

    Participants with severe hepatic impairment received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.

    Drug: Efinopegdutide

  • Experimental
    Efinopegdutide in Healthy-Matched Control Group

    Healthy matched participants received a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.

    Drug: Efinopegdutide

Interventions

  • Subcutaneous injection administered at a dose of 7 mg

    Also known as: MK-6024, HM12525A, JNJ-64565111

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-inf.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

  2. Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-last.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

  3. Maximum Plasma Concentration (Cmax) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the Cmax.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

  4. Time to Maximum Concentration (Tmax) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the Tmax of efinopegdutide.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

  5. Apparent Terminal Half-life (t/12) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the t1/2.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

  6. Apparent Total Clearance (CL/F) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the CL/F.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

  7. Apparent Volume of Distribution (Vz/F) of Efinopegdutide

    Blood samples collected at multiple timepoints post-dose were used to determine the Vz/F.

    Time frame: At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35

Secondary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

    Time frame: Up to 35 days

  2. Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

    Time frame: Up to 35 days

07

Results

Posted Oct 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Started886
Completed886
Not completed000

Outcome measures

PrimaryArea Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-inf.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Geometric mean · hr*μg/mL
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide
hr*μg/mLEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Efinopegdutide143 (120 to 169)152 (106 to 219)146 (81.8 to 262)
Statistical analysis
  • Efinopegdutide in Participants With Moderate Hepatic Impairment vs Efinopegdutide in Healthy-Matched Control Group · Geometric mean ratio: 0.97 · 90% CI 0.61 to 1.54
  • Efinopegdutide in Participants With Severe Hepatic Impairment vs Efinopegdutide in Healthy-Matched Control Group · Geometric mean ratio: 1.04 · 90% CI 0.63 to 1.71
PrimaryArea Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the AUC0-last.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Geometric mean · hr*μg/mL
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide
hr*μg/mLEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Efinopegdutide133 (113 to 156)125 (80.8 to 193)134 (70.2 to 255)
Statistical analysis
  • Efinopegdutide in Participants With Moderate Hepatic Impairment vs Efinopegdutide in Healthy-Matched Control Group · Geometric mean ratio: 0.99 · 90% CI 0.60 to 1.65
  • Efinopegdutide in Participants With Severe Hepatic Impairment vs Efinopegdutide in Healthy-Matched Control Group · Geometric mean ratio: 0.93 · 90% CI 0.53 to 1.65
PrimaryMaximum Plasma Concentration (Cmax) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the Cmax.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Geometric mean · μg/mL
Maximum Plasma Concentration (Cmax) of Efinopegdutide
μg/mLEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Maximum Plasma Concentration (Cmax) of Efinopegdutide0.348 (0.282 to 0.429)0.404 (0.242 to 0.675)0.474 (0.253 to 0.890)
Statistical analysis
  • Efinopegdutide in Participants With Moderate Hepatic Impairment vs Efinopegdutide in Healthy-Matched Control Group · Geometric mean ratio: 0.73 · 90% CI 0.44 to 1.21
  • Efinopegdutide in Participants With Severe Hepatic Impairment vs Efinopegdutide in Healthy-Matched Control Group · Geometric mean ratio: 0.85 · 90% CI 0.47 to 1.53
PrimaryTime to Maximum Concentration (Tmax) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the Tmax of efinopegdutide.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Median · hour
Time to Maximum Concentration (Tmax) of Efinopegdutide
hourEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Time to Maximum Concentration (Tmax) of Efinopegdutide120.00 (96.00 to 310.93)72.04 (24.00 to 144.00)83.78 (48.00 to 167.25)
PrimaryApparent Terminal Half-life (t/12) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the t1/2.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Geometric mean · hour
Apparent Terminal Half-life (t/12) of Efinopegdutide
hourEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Apparent Terminal Half-life (t/12) of Efinopegdutide146 ± 13.5149 ± 26.0115 ± 32.3
PrimaryApparent Total Clearance (CL/F) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the CL/F.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Geometric mean · L/hr
Apparent Total Clearance (CL/F) of Efinopegdutide
L/hrEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Apparent Total Clearance (CL/F) of Efinopegdutide0.0491 ± 16.50.0460 ± 40.80.0478 ± 60.0
PrimaryApparent Volume of Distribution (Vz/F) of Efinopegdutide

Blood samples collected at multiple timepoints post-dose were used to determine the Vz/F.

Time frame:
At pre-specified timepoints on Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 11, Day 14, Day 21, and Day 35
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vz/F) of Efinopegdutide
LitersEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Apparent Volume of Distribution (Vz/F) of Efinopegdutide10.3 ± 17.99.88 ± 57.87.94 ± 91.7
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

Time frame:
Up to 35 days
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Number of Participants Who Experienced an Adverse Event (AE)344
SecondaryNumber of Participants Who Discontinued Study Intervention Due to an AE

An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality.

Time frame:
Up to 35 days
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Number of Participants Who Discontinued Study Intervention Due to an AE000

Adverse events

Collected over Up to 35 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efinopegdutide in Participants With Moderate Hepatic Impairment0/8 (0%)1/8 (12.5%)2/8 (25%)
Efinopegdutide in Participants With Severe Hepatic Impairment0/8 (0%)0/8 (0%)4/8 (50%)
Efinopegdutide in Healthy-Matched Control Group0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
Multiple injuriesInjury, poisoning and procedural complications1/80/80/6
Most frequent other events
Most frequent other events
EventEfinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control Group
HeadacheNervous system disorders1/80/83/6
FlatulenceGastrointestinal disorders0/80/82/6
DyspepsiaGastrointestinal disorders0/81/81/6
NeutropeniaBlood and lymphatic system disorders0/81/80/6
ConstipationGastrointestinal disorders0/81/80/6
VomitingGastrointestinal disorders0/81/80/6
HyperbilirubinaemiaHepatobiliary disorders0/81/80/6
Neck painMusculoskeletal and connective tissue disorders1/80/80/6
Hepatic encephalopathyNervous system disorders0/81/80/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Efinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control GroupTotal
Mean57.5 ± 9.548.5 ± 10.556.2 ± 7.153.9 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Efinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control GroupTotal
Female4037
Male48315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Efinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control GroupTotal
Hispanic or Latino67619
Not Hispanic or Latino2103
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Efinopegdutide in Participants With Moderate Hepatic ImpairmentEfinopegdutide in Participants With Severe Hepatic ImpairmentEfinopegdutide in Healthy-Matched Control GroupTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White88521
More than one race0000
Unknown or Not Reported0000
08

Study locations

4 sites
  • Clinical Pharmacology of Miami ( Site 0005)
    Miami, Florida 33014-3616, United States
  • Advanced Pharma CR, LLC ( Site 0001)
    Miami, Florida 33147, United States
  • Genesis Clinical Research, LLC ( Site 0006)
    Tampa, Florida 33603, United States
  • American Research Corporation ( Site 0002)
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2024, 12 months.

Results were first posted in Oct 2025, 10 months after primary completion.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 12 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 25, 2023
StartActual
Nov 21, 2023
Primary completionActual
Dec 5, 2024
CompletionActual
Dec 5, 2024
Results first posted
Oct 22, 2025
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06052566
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Nov 21, 2023
Primary completion
Dec 5, 2024
Completion
Dec 5, 2024
Results posted
Oct 22, 2025
Last update
Oct 22, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion